214870 — NewGLab Pharma Co Income Statement
0.000.00%
Last trade - 00:00TechnologySpeculativeMicro Cap
Annual income statement for NewGLab Pharma Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
R2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | Annual Audited Accounts | Annual Audited Accounts | ARS | Annual Audited Accounts | Annual Audited Accounts |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 95,820 | 54,417 | 29,354 | 21,711 | 12,621 |
| Cost of Revenue | |||||
| Gross Profit | 26,555 | 9,246 | 3,350 | 3,556 | 955 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 99,045 | 72,922 | 82,392 | 56,305 | 28,083 |
| Operating Profit | -3,225 | -18,505 | -53,038 | -34,594 | -15,462 |
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -4,057 | -23,444 | -53,879 | -74,389 | -29.3 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -4,006 | -22,609 | -51,923 | -71,957 | 904 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | -4,006 | -22,609 | -50,511 | -69,550 | 1,991 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -4,006 | -22,609 | -50,511 | -69,550 | 1,991 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -134 | -805 | -1,125 | -2,091 | 5.33 |
| Dividends per Share |